BBIO

SEC source: 0001470831-26-000636 · wk-form4_1782338786.xml · derivative · entry 6

Cook Jennifer E. · CIK 0001754371 · Director

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 5,277

Underlying: Common Stock · 5,277 shares

Expires 2036-06-21

F4 · derivative.exercise_date: The shares underlying the stock option vest in full on June 22, 2027, subject to the Reporting Person's continued service on the Issuer's board of directors through the vesting date.

SEC source: 0001470831-26-000636 · wk-form4_1782338786.xml · nonDerivative · entry 1

Cook Jennifer E. · CIK 0001754371 · Director

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 10,579

F1 · kind: Grant of restricted stock units ("RSUs") under the Issuer's 2021 Amended and Restated BridgeBio Pharma, Inc. Stock Option and Incentive Plan. The RSUs vest in full on June 22, 2027, subject to the Reporting Person's continued service on the Issuer's board of directors through the vesting date.

F2 · price: Each RSU represents a contingent right to receive one share of the Issuer's Common Stock.

SEC source: 0001470831-26-000634 · wk-form4_1782338774.xml · derivative · entry 3

Lo Andrew · CIK 0001679076 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 5,277

Underlying: Common Stock · 5,277 shares

Expires 2036-06-21

F3 · derivative.exercise_date: The shares underlying the stock option vest in full on June 22, 2027, subject to the Reporting Person's continued service on the Issuer's board of directors through the vesting date.

SEC source: 0001470831-26-000634 · wk-form4_1782338774.xml · nonDerivative · entry 1

Lo Andrew · CIK 0001679076 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 18,079

F1 · kind: Grant of restricted stock units ("RSUs") under the Issuer's 2021 Amended and Restated BridgeBio Pharma, Inc. Stock Option and Incentive Plan. The RSUs vest in full on June 22, 2027, subject to the Reporting Person's continued service on the Issuer's board of directors through the vesting date.

F2 · price: Each RSU represents a contingent right to receive one share of the Issuer's Common Stock.

SEC source: 0001470831-26-000633 · wk-form4_1782338768.xml · derivative · entry 2

HOMCY CHARLES J · CIK 0001192591 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 5,277

Underlying: Common Stock · 5,277 shares

Expires 2036-06-21

F3 · derivative.exercise_date: The shares underlying the stock option vest in full on June 22, 2027, subject to the Reporting Person's continued service on the Issuer's board of directors through the vesting date.

SEC source: 0001470831-26-000633 · wk-form4_1782338768.xml · nonDerivative · entry 1

HOMCY CHARLES J · CIK 0001192591 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 919,876

F1 · kind: Grant of restricted stock units ("RSUs") under the Issuer's 2021 Amended and Restated BridgeBio Pharma, Inc. Stock Option and Incentive Plan. The RSUs vest in full on June 22, 2027, subject to the Reporting Person's continued service on the Issuer's board of directors through the vesting date.

F2 · price: Each RSU represents a contingent right to receive one share of the Issuer's Common Stock.

SEC source: 0001470831-26-000632 · wk-form4_1782338761.xml · derivative · entry 2

AGUIAR ERIC · CIK 0001262325 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 5,277

Underlying: Common Stock · 5,277 shares

Expires 2036-06-21

F3 · derivative.exercise_date: The shares underlying the stock option vest in full on June 22, 2027, subject to the Reporting Person's continued service on the Issuer's board of directors through the vesting date.

SEC source: 0001470831-26-000632 · wk-form4_1782338761.xml · nonDerivative · entry 1

AGUIAR ERIC · CIK 0001262325 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 10,579

F1 · kind: Grant of restricted stock units ("RSUs") under the Issuer's 2021 Amended and Restated BridgeBio Pharma, Inc. Stock Option and Incentive Plan. The RSUs vest in full on June 22, 2027, subject to the Reporting Person's continued service on the Issuer's board of directors through the vesting date.

F2 · price: Each RSU represents a contingent right to receive one share of the Issuer's Common Stock.

SEC source: 0001470831-26-000628 · wk-form4_1782338732.xml · derivative · entry 3

MOMTAZEE JAMES C · CIK 0001209181 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 5,277

Underlying: Common Stock · 5,277 shares

Expires 2036-06-21

F4 · derivative.exercise_date: The shares underlying the stock option vest in full on June 22, 2027, subject to the Reporting Person's continued service on the Issuer's board of directors through the vesting date.

SEC source: 0001470831-26-000628 · wk-form4_1782338732.xml · nonDerivative · entry 1

MOMTAZEE JAMES C · CIK 0001209181 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 19,070

F1 · kind: Grant of restricted stock units ("RSUs") under the Issuer's 2021 Amended and Restated BridgeBio Pharma, Inc. Stock Option and Incentive Plan. The RSUs vest in full on June 22, 2027, subject to the Reporting Person's continued service on the Issuer's board of directors through the vesting date.

F2 · price: Each RSU represents a contingent right to receive one share of the Issuer's Common Stock.

F3 · balance_after: The 80,000 shares reported herein as indirectly owned through the James C. Momtazee Revocable Trust (the "Trust") were previously reported as directly owned by the Reporting Person.

SEC source: 0001470831-26-000627 · wk-form4_1782338726.xml · derivative · entry 3

MCCORMICK FRANK · CIK 0001257809 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 5,277

Underlying: Common Stock · 5,277 shares

Expires 2036-06-21

F6 · derivative.exercise_date: The shares underlying the stock option vest in full on June 22, 2027, subject to the Reporting Person's continued service on the Issuer's board of directors through the vesting date.

SEC source: 0001470831-26-000627 · wk-form4_1782338726.xml · nonDerivative · entry 1

MCCORMICK FRANK · CIK 0001257809 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 10,579

F1 · kind: Grant of restricted stock units ("RSUs") under the Issuer's 2021 Amended and Restated BridgeBio Pharma, Inc. Stock Option and Incentive Plan. The RSUs vest in full on June 22, 2027, subject to the Reporting Person's continued service on the Issuer's board of directors through the vesting date.

F2 · price: Each RSU represents a contingent right to receive one share of the Issuer's Common Stock.

F3 · balance_after: The Reporting Person previously reported a transfer of 352,290 shares on a Form 4 filed June 25, 2024. The reported transfer did not occur, and no change in beneficial ownership took place at that time. The ownership amounts reported herein reflect the Reporting Person's correct holdings and the transfer described in Footnotes 4 and 5.

F4 · balance_after: Excludes 428,976 shares that were previously held directly by the Reporting Person and were transferred to the Reporting Person's trust account on June 3, 2026.

SEC source: 0001470831-26-000626 · wk-form4_1782338719.xml · derivative · entry 3

Dachille Douglas A. · CIK 0001652908 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 5,277

Underlying: Common Stock · 5,277 shares

Expires 2036-06-21

F4 · derivative.exercise_date: The shares underlying the stock option vest in full on June 22, 2027, subject to the Reporting Person's continued service on the Issuer's board of directors through the vesting date.

SEC source: 0001470831-26-000626 · wk-form4_1782338719.xml · nonDerivative · entry 1

Dachille Douglas A. · CIK 0001652908 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 10,579

F1 · kind: Grant of restricted stock units ("RSUs") under the Issuer's 2021 Amended and Restated BridgeBio Pharma, Inc. Stock Option and Incentive Plan. The RSUs vest in full on June 22, 2027, subject to the Reporting Person's continued service on the Issuer's board of directors through the vesting date.

F2 · price: Each RSU represents a contingent right to receive one share of the Issuer's Common Stock.

SEC source: 0001470831-26-000625 · wk-form4_1782338712.xml · derivative · entry 2

Satvat Ali J. · CIK 0001621788 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 5,277

Underlying: Common Stock · 5,277 shares

Expires 2036-06-21

F3 · derivative.exercise_date: The shares underlying the stock option vest in full on June 22, 2027, subject to the Reporting Person's continued service on the Issuer's board of directors through the vesting date.

SEC source: 0001470831-26-000625 · wk-form4_1782338712.xml · nonDerivative · entry 1

Satvat Ali J. · CIK 0001621788 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 169,983

F1 · kind: Grant of restricted stock units ("RSUs") under the Issuer's 2021 Amended and Restated BridgeBio Pharma, Inc. Stock Option and Incentive Plan. The RSUs vest in full on June 22, 2027, subject to the Reporting Person's continued service on the Issuer's board of directors through the vesting date.

F2 · price: Each RSU represents a contingent right to receive one share of the Issuer's Common Stock.

SEC source: 0001470831-26-000569 · wk-form4_1782254762.xml · nonDerivative · entry 1

HOMCY CHARLES J · CIK 0001192591 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 915,886

F1 · shares: Represents number of shares of the Issuer's Common Stock withheld to satisfy the Reporting Person's tax obligation in connection with the vesting of 2,196 shares of Common Stock underlying the Reporting Person's RSUs.

SEC source: 0001470831-26-000550 · wk-form4_1781729104.xml · derivative · entry 6

Cook Jennifer E. · CIK 0001754371 · Director

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 34,334

Underlying: Common Stock · 17,167 shares

Expires 2033-06-21

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 sales plan adopted by the Reporting Person on March 16, 2026.

F5 · derivative.exercise_date: 1/3rd of the shares underlying the option will vest on June 21, 2024; thereafter, 1/3rd of the underlying shares will vest on an annual basis, so that all of the underlying shares will be vested on June 21, 2026, subject to the optionee's continued service on the Board of Directors of the Company.

SEC source: 0001470831-26-000550 · wk-form4_1781729104.xml · derivative · entry 5

Cook Jennifer E. · CIK 0001754371 · Director

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 39,000

Underlying: Common Stock · 65,921 shares

Expires 2032-06-22

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 sales plan adopted by the Reporting Person on March 16, 2026.

F4 · derivative.exercise_date: 1/3rd of the shares underlying the option will vest on June 22, 2023; thereafter, 1/3rd of the remaining underlying shares will vest on an annual basis, so that all of the underlying shares will be vested on the June 22, 2025, subject to the optionee's continued service on the Board of Directors of the Company.

SEC source: 0001470831-26-000550 · wk-form4_1781729104.xml · nonDerivative · entry 4

Cook Jennifer E. · CIK 0001754371 · Director

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 6,589

F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 sales plan adopted by the Reporting Person on March 16, 2026.

F3 · price: Represents the weighted average sale price of the shares sold from $67.10 to $67.20 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price for all transactions within the range set forth in this footnote.

SEC source: 0001470831-26-000550 · wk-form4_1781729104.xml · nonDerivative · entry 3

Cook Jennifer E. · CIK 0001754371 · Director

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 8,092

F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 sales plan adopted by the Reporting Person on March 16, 2026.

F2 · price: Represents the weighted average sale price of the shares sold from $66.10 to $67.095 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price for all transactions within the range set forth in this footnote.

SEC source: 0001470831-26-000550 · wk-form4_1781729104.xml · nonDerivative · entry 2

Cook Jennifer E. · CIK 0001754371 · Director

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 96,829

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 sales plan adopted by the Reporting Person on March 16, 2026.

SEC source: 0001470831-26-000550 · wk-form4_1781729104.xml · nonDerivative · entry 1

Cook Jennifer E. · CIK 0001754371 · Director

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 79,662

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 sales plan adopted by the Reporting Person on March 16, 2026.

SEC source: 0001470831-26-000523 · wk-form4_1780956089.xml · nonDerivative · entry 14

Kumar Neil · CIK 0001742485 · Director · Chief Executive Officer

10b5-1 filing: Plan reported

Ownership: Indirect · By Kumar Haldea Revocable Trust, of which the Reporting Person is a co-trustee.

Disclosed balance after: 4,318,447

F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 sales plan adopted by the Reporting Person on March 31, 2025.

F9 · price: Represents the weighted average sale price of the shares sold from $68.61 to $69.51 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price for all transactions within the range set forth in this footnote.

F3 · ownership.nature: The Reporting Person disclaims beneficial ownership of these shares except to the extent of his pecuniary interest therein, if any, and this report shall not be deemed to be an admission that such shares are beneficially owned by the Reporting Person for Section 16 or any other purpose.

SEC source: 0001470831-26-000523 · wk-form4_1780956089.xml · nonDerivative · entry 13

Kumar Neil · CIK 0001742485 · Director · Chief Executive Officer

10b5-1 filing: Plan reported

Ownership: Indirect · By Kumar Haldea Revocable Trust, of which the Reporting Person is a co-trustee.

Disclosed balance after: 4,322,862

F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 sales plan adopted by the Reporting Person on March 31, 2025.

F8 · price: Represents the weighted average sale price of the shares sold from $67.61 to $68.605 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price for all transactions within the range set forth in this footnote.

F3 · ownership.nature: The Reporting Person disclaims beneficial ownership of these shares except to the extent of his pecuniary interest therein, if any, and this report shall not be deemed to be an admission that such shares are beneficially owned by the Reporting Person for Section 16 or any other purpose.

SEC source: 0001470831-26-000523 · wk-form4_1780956089.xml · nonDerivative · entry 12

Kumar Neil · CIK 0001742485 · Director · Chief Executive Officer

10b5-1 filing: Plan reported

Ownership: Indirect · By Kumar Haldea Revocable Trust, of which the Reporting Person is a co-trustee.

Disclosed balance after: 4,331,299

F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 sales plan adopted by the Reporting Person on March 31, 2025.

F7 · price: Represents the weighted average sale price of the shares sold from $66.59 to $67.58 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price for all transactions within the range set forth in this footnote.

F3 · ownership.nature: The Reporting Person disclaims beneficial ownership of these shares except to the extent of his pecuniary interest therein, if any, and this report shall not be deemed to be an admission that such shares are beneficially owned by the Reporting Person for Section 16 or any other purpose.

SEC source: 0001470831-26-000523 · wk-form4_1780956089.xml · nonDerivative · entry 11

Kumar Neil · CIK 0001742485 · Director · Chief Executive Officer

10b5-1 filing: Plan reported

Ownership: Indirect · By Kumar Haldea Family Irrevocable Trust, of which the Reporting Person is a co-trustee.

Disclosed balance after: 515,686

F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 sales plan adopted by the Reporting Person on March 31, 2025.

F9 · price: Represents the weighted average sale price of the shares sold from $68.61 to $69.51 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price for all transactions within the range set forth in this footnote.

F3 · ownership.nature: The Reporting Person disclaims beneficial ownership of these shares except to the extent of his pecuniary interest therein, if any, and this report shall not be deemed to be an admission that such shares are beneficially owned by the Reporting Person for Section 16 or any other purpose.

SEC source: 0001470831-26-000523 · wk-form4_1780956089.xml · nonDerivative · entry 10

Kumar Neil · CIK 0001742485 · Director · Chief Executive Officer

10b5-1 filing: Plan reported

Ownership: Indirect · By Kumar Haldea Family Irrevocable Trust, of which the Reporting Person is a co-trustee.

Disclosed balance after: 520,102

F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 sales plan adopted by the Reporting Person on March 31, 2025.

F8 · price: Represents the weighted average sale price of the shares sold from $67.61 to $68.605 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price for all transactions within the range set forth in this footnote.

F3 · ownership.nature: The Reporting Person disclaims beneficial ownership of these shares except to the extent of his pecuniary interest therein, if any, and this report shall not be deemed to be an admission that such shares are beneficially owned by the Reporting Person for Section 16 or any other purpose.

SEC source: 0001470831-26-000523 · wk-form4_1780956089.xml · nonDerivative · entry 9

Kumar Neil · CIK 0001742485 · Director · Chief Executive Officer

10b5-1 filing: Plan reported

Ownership: Indirect · By Kumar Haldea Family Irrevocable Trust, of which the Reporting Person is a co-trustee.

Disclosed balance after: 528,539

F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 sales plan adopted by the Reporting Person on March 31, 2025.

F7 · price: Represents the weighted average sale price of the shares sold from $66.59 to $67.58 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price for all transactions within the range set forth in this footnote.

F3 · ownership.nature: The Reporting Person disclaims beneficial ownership of these shares except to the extent of his pecuniary interest therein, if any, and this report shall not be deemed to be an admission that such shares are beneficially owned by the Reporting Person for Section 16 or any other purpose.

SEC source: 0001470831-26-000523 · wk-form4_1780956089.xml · nonDerivative · entry 8

Kumar Neil · CIK 0001742485 · Director · Chief Executive Officer

10b5-1 filing: Plan reported

Ownership: Indirect · By Kumar Haldea Revocable Trust, of which the Reporting Person is a co-trustee.

Disclosed balance after: 4,338,447

F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 sales plan adopted by the Reporting Person on March 31, 2025.

F6 · price: Represents the weighted average sale price of the shares sold from $68.17 to $68.38 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price for all transactions within the range set forth in this footnote.

F3 · ownership.nature: The Reporting Person disclaims beneficial ownership of these shares except to the extent of his pecuniary interest therein, if any, and this report shall not be deemed to be an admission that such shares are beneficially owned by the Reporting Person for Section 16 or any other purpose.

SEC source: 0001470831-26-000523 · wk-form4_1780956089.xml · nonDerivative · entry 7

Kumar Neil · CIK 0001742485 · Director · Chief Executive Officer

10b5-1 filing: Plan reported

Ownership: Indirect · By Kumar Haldea Revocable Trust, of which the Reporting Person is a co-trustee.

Disclosed balance after: 4,338,897

F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 sales plan adopted by the Reporting Person on March 31, 2025.

F5 · price: Represents the weighted average sale price of the shares sold from $67.17 to $68.16 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price for all transactions within the range set forth in this footnote.

F3 · ownership.nature: The Reporting Person disclaims beneficial ownership of these shares except to the extent of his pecuniary interest therein, if any, and this report shall not be deemed to be an admission that such shares are beneficially owned by the Reporting Person for Section 16 or any other purpose.

SEC source: 0001470831-26-000523 · wk-form4_1780956089.xml · nonDerivative · entry 6

Kumar Neil · CIK 0001742485 · Director · Chief Executive Officer

10b5-1 filing: Plan reported

Ownership: Indirect · By Kumar Haldea Revocable Trust, of which the Reporting Person is a co-trustee.

Disclosed balance after: 4,354,818

F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 sales plan adopted by the Reporting Person on March 31, 2025.

F4 · price: Represents the weighted average sale price of the shares sold from $66.15 to $67.14 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price for all transactions within the range set forth in this footnote.

F3 · ownership.nature: The Reporting Person disclaims beneficial ownership of these shares except to the extent of his pecuniary interest therein, if any, and this report shall not be deemed to be an admission that such shares are beneficially owned by the Reporting Person for Section 16 or any other purpose.

SEC source: 0001470831-26-000523 · wk-form4_1780956089.xml · nonDerivative · entry 5

Kumar Neil · CIK 0001742485 · Director · Chief Executive Officer

10b5-1 filing: Plan reported

Ownership: Indirect · By Kumar Haldea Revocable Trust, of which the Reporting Person is a co-trustee.

Disclosed balance after: 4,356,247

F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 sales plan adopted by the Reporting Person on March 31, 2025.

F2 · price: Represents the weighted average sale price of the shares sold from $65.145 to $66.12 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price for all transactions within the range set forth in this footnote.

F3 · ownership.nature: The Reporting Person disclaims beneficial ownership of these shares except to the extent of his pecuniary interest therein, if any, and this report shall not be deemed to be an admission that such shares are beneficially owned by the Reporting Person for Section 16 or any other purpose.

SEC source: 0001470831-26-000523 · wk-form4_1780956089.xml · nonDerivative · entry 4

Kumar Neil · CIK 0001742485 · Director · Chief Executive Officer

10b5-1 filing: Plan reported

Ownership: Indirect · By Kumar Haldea Family Irrevocable Trust, of which the Reporting Person is a co-trustee.

Disclosed balance after: 535,686

F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 sales plan adopted by the Reporting Person on March 31, 2025.

F6 · price: Represents the weighted average sale price of the shares sold from $68.17 to $68.38 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price for all transactions within the range set forth in this footnote.

F3 · ownership.nature: The Reporting Person disclaims beneficial ownership of these shares except to the extent of his pecuniary interest therein, if any, and this report shall not be deemed to be an admission that such shares are beneficially owned by the Reporting Person for Section 16 or any other purpose.

SEC source: 0001470831-26-000523 · wk-form4_1780956089.xml · nonDerivative · entry 3

Kumar Neil · CIK 0001742485 · Director · Chief Executive Officer

10b5-1 filing: Plan reported

Ownership: Indirect · By Kumar Haldea Family Irrevocable Trust, of which the Reporting Person is a co-trustee.

Disclosed balance after: 536,136

F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 sales plan adopted by the Reporting Person on March 31, 2025.

F5 · price: Represents the weighted average sale price of the shares sold from $67.17 to $68.16 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price for all transactions within the range set forth in this footnote.

F3 · ownership.nature: The Reporting Person disclaims beneficial ownership of these shares except to the extent of his pecuniary interest therein, if any, and this report shall not be deemed to be an admission that such shares are beneficially owned by the Reporting Person for Section 16 or any other purpose.

SEC source: 0001470831-26-000523 · wk-form4_1780956089.xml · nonDerivative · entry 2

Kumar Neil · CIK 0001742485 · Director · Chief Executive Officer

10b5-1 filing: Plan reported

Ownership: Indirect · By Kumar Haldea Family Irrevocable Trust, of which the Reporting Person is a co-trustee.

Disclosed balance after: 552,057

F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 sales plan adopted by the Reporting Person on March 31, 2025.

F4 · price: Represents the weighted average sale price of the shares sold from $66.15 to $67.14 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price for all transactions within the range set forth in this footnote.

F3 · ownership.nature: The Reporting Person disclaims beneficial ownership of these shares except to the extent of his pecuniary interest therein, if any, and this report shall not be deemed to be an admission that such shares are beneficially owned by the Reporting Person for Section 16 or any other purpose.

SEC source: 0001470831-26-000523 · wk-form4_1780956089.xml · nonDerivative · entry 1

Kumar Neil · CIK 0001742485 · Director · Chief Executive Officer

10b5-1 filing: Plan reported

Ownership: Indirect · By Kumar Haldea Family Irrevocable Trust, of which the Reporting Person is a co-trustee.

Disclosed balance after: 553,486

F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 sales plan adopted by the Reporting Person on March 31, 2025.

F2 · price: Represents the weighted average sale price of the shares sold from $65.145 to $66.12 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price for all transactions within the range set forth in this footnote.

F3 · ownership.nature: The Reporting Person disclaims beneficial ownership of these shares except to the extent of his pecuniary interest therein, if any, and this report shall not be deemed to be an admission that such shares are beneficially owned by the Reporting Person for Section 16 or any other purpose.

SEC source: 0001470831-26-000488 · wk-form4_1779828852.xml · nonDerivative · entry 5

Kumar Neil · CIK 0001742485 · Director · Chief Executive Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 243,327

F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 sales plan adopted by the Reporting Person on March 31, 2025.

F6 · price: Represents the weighted average sale price of the shares sold from $70.86 to $70.97 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price for all transactions within the range set forth in this footnote.

SEC source: 0001470831-26-000488 · wk-form4_1779828852.xml · nonDerivative · entry 4

Kumar Neil · CIK 0001742485 · Director · Chief Executive Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 244,127

F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 sales plan adopted by the Reporting Person on March 31, 2025.

F5 · price: Represents the weighted average sale price of the shares sold from $69.86 to $70.85 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price for all transactions within the range set forth in this footnote.

SEC source: 0001470831-26-000488 · wk-form4_1779828852.xml · nonDerivative · entry 3

Kumar Neil · CIK 0001742485 · Director · Chief Executive Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 255,377

F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 sales plan adopted by the Reporting Person on March 31, 2025.

F4 · price: Represents the weighted average sale price of the shares sold from $68.81 to $69.78 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price for all transactions within the range set forth in this footnote.

SEC source: 0001470831-26-000488 · wk-form4_1779828852.xml · nonDerivative · entry 2

Kumar Neil · CIK 0001742485 · Director · Chief Executive Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 260,449

F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 sales plan adopted by the Reporting Person on March 31, 2025.

F3 · price: Represents the weighted average sale price of the shares sold from $67.81 to $68.80 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price for all transactions within the range set forth in this footnote.

SEC source: 0001470831-26-000488 · wk-form4_1779828852.xml · nonDerivative · entry 1

Kumar Neil · CIK 0001742485 · Director · Chief Executive Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 267,174

F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 sales plan adopted by the Reporting Person on March 31, 2025.

F2 · price: Represents the weighted average sale price of the shares sold from $66.81 to $67.80 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price for all transactions within the range set forth in this footnote.

SEC source: 0001470831-26-000473 · wk-form4_1779222603.xml · nonDerivative · entry 3

Trimarchi Thomas · CIK 0002030813 · President and CFO

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 359,194

F2 · kind: This transaction was effected pursuant to a Rule 10b5-1 sales plan adopted by the Reporting Person on March 31, 2025.

F4 · price: Represents the weighted average sale price of the shares sold from $65.54 to $66.21 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price for all transactions within the range set forth in this footnote.

SEC source: 0001470831-26-000473 · wk-form4_1779222603.xml · nonDerivative · entry 2

Trimarchi Thomas · CIK 0002030813 · President and CFO

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 362,389

F2 · kind: This transaction was effected pursuant to a Rule 10b5-1 sales plan adopted by the Reporting Person on March 31, 2025.

F3 · price: Represents the weighted average sale price of the shares sold from $64.34 to $65.33 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price for all transactions within the range set forth in this footnote.

SEC source: 0001470831-26-000471 · wk-form4_1779222400.xml · nonDerivative · entry 1

Apuli Maricel · CIK 0002058197 · Chief Accounting Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 129,401

F1 · shares: Represents number of shares of the Issuer's Common Stock withheld to satisfy the Reporting Person's tax obligation in connection with the vesting of 9,260 shares of Common Stock underlying the Reporting Person's RSUs.

SEC source: 0001470831-26-000473 · wk-form4_1779222603.xml · nonDerivative · entry 1

Trimarchi Thomas · CIK 0002030813 · President and CFO

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 372,845

F1 · shares: Represents number of shares of the Issuer's Common Stock withheld to satisfy the Reporting Person's tax obligation in connection with the vesting of 41,193 shares of Common Stock underlying the Reporting Person's RSUs.

SEC source: 0001470831-26-000472 · wk-form4_1779222471.xml · derivative · entry 11

Kumar Neil · CIK 0001742485 · Director · Chief Executive Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 97,794

Underlying: Common Stock · 6,519 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock.

F7 · derivative.exercise_date: The RSUs will vest with respect to 1/16th of the underlying shares on May 16, 2026. Thereafter, 1/16th of the underlying shares vest on a quarterly basis, subject to the Reporting Person's continued service with the Issuer or any of its subsidiaries through each vesting date. The RSUs have no expiration date.

F7 · derivative.expiration_date: The RSUs will vest with respect to 1/16th of the underlying shares on May 16, 2026. Thereafter, 1/16th of the underlying shares vest on a quarterly basis, subject to the Reporting Person's continued service with the Issuer or any of its subsidiaries through each vesting date. The RSUs have no expiration date.

SEC source: 0001470831-26-000472 · wk-form4_1779222471.xml · derivative · entry 10

Kumar Neil · CIK 0001742485 · Director · Chief Executive Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 127,092

Underlying: Common Stock · 11,553 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock.

F6 · derivative.exercise_date: The RSUs vested with respect to 1/16th of the underlying shares on May 16, 2025. Thereafter, 1/16th of the underlying shares vest on a quarterly basis, subject to the Reporting Person's continued service with the Issuer or any of its subsidiaries through each vesting date. The RSUs have no expiration date.

F6 · derivative.expiration_date: The RSUs vested with respect to 1/16th of the underlying shares on May 16, 2025. Thereafter, 1/16th of the underlying shares vest on a quarterly basis, subject to the Reporting Person's continued service with the Issuer or any of its subsidiaries through each vesting date. The RSUs have no expiration date.

SEC source: 0001470831-26-000472 · wk-form4_1779222471.xml · derivative · entry 9

Kumar Neil · CIK 0001742485 · Director · Chief Executive Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 137,195

Underlying: Common Stock · 19,599 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock.

F5 · derivative.exercise_date: The RSUs vested with respect to 1/16th of the underlying shares on May 16, 2024. Thereafter, 1/16th of the underlying shares vest on a quarterly basis, subject to the Reporting Person's continued service with the Issuer or any of its subsidiaries through each vesting date. The RSUs have no expiration date.

F5 · derivative.expiration_date: The RSUs vested with respect to 1/16th of the underlying shares on May 16, 2024. Thereafter, 1/16th of the underlying shares vest on a quarterly basis, subject to the Reporting Person's continued service with the Issuer or any of its subsidiaries through each vesting date. The RSUs have no expiration date.

SEC source: 0001470831-26-000472 · wk-form4_1779222471.xml · derivative · entry 8

Kumar Neil · CIK 0001742485 · Director · Chief Executive Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 100,632

Underlying: Common Stock · 33,544 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock.

F4 · derivative.exercise_date: The RSUs vested with respect to 1/16th of the underlying shares on May 16, 2023. Thereafter, 1/16th of the underlying shares vest on a quarterly basis, subject to the Reporting Person's continued service with the Issuer or any of its subsidiaries through each vesting date. The RSUs have no expiration date.

F4 · derivative.expiration_date: The RSUs vested with respect to 1/16th of the underlying shares on May 16, 2023. Thereafter, 1/16th of the underlying shares vest on a quarterly basis, subject to the Reporting Person's continued service with the Issuer or any of its subsidiaries through each vesting date. The RSUs have no expiration date.